相似文献
1
Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
Tex Heart Inst J. 2011;38(2):160-2.
2
Atherogenic dyslipidemia in the cardiometabolic syndrome.
J Cardiometab Syndr. 2006 Spring;1(2):153-5. doi: 10.1111/j.1559-4564.2006.05671.x.
3
Atherogenic dyslipidemia.
J Cardiometab Syndr. 2006 Summer;1(3):166-7.
4
Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.
Heart Vessels. 2014 Jan;29(1):35-41. doi: 10.1007/s00380-013-0330-5. Epub 2013 Mar 21.
5
Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: a prospective observational study.
JACC Cardiovasc Interv. 2015 May;8(6):800-811. doi: 10.1016/j.jcin.2014.11.025.
6
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.
Vasc Health Risk Manag. 2009;5:757-65. Epub 2009 Sep 18.
7
Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
Arch Cardiovasc Dis. 2018 Nov;111(11):634-643. doi: 10.1016/j.acvd.2017.07.007. Epub 2017 Dec 2.
8
Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
Nat Rev Cardiol. 2018 Jan 16;15(2):75-76. doi: 10.1038/nrcardio.2017.221.
9
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Vasc Health Risk Manag. 2014 May 7;10:279-90. doi: 10.2147/VHRM.S58694. eCollection 2014.
10
[Treatment of dyslipidemia in 2014: European versus American guidelines].
Rev Med Suisse. 2014 Aug 27;10(439):1534-7.
引用本文的文献
1
Obesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study.
PLoS One. 2025 Jan 30;20(1):e0316527. doi: 10.1371/journal.pone.0316527. eCollection 2025.
2
Glucose and Lipid Metabolism Disorders in Adults with Spinal Muscular Atrophy Type 3.
Diagnostics (Basel). 2024 Sep 19;14(18):2078. doi: 10.3390/diagnostics14182078.
3
The performance of lipid profiles and ratios as a predictor of arterial stiffness measured by brachial-ankle pulse wave velocity in type 2 diabetic patients.
F1000Res. 2023 Jun 5;11:1582. doi: 10.12688/f1000research.128627.2. eCollection 2022.
4
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond.
Am J Prev Cardiol. 2024 Jun 25;19:100701. doi: 10.1016/j.ajpc.2024.100701. eCollection 2024 Sep.
5
Physical activity in metabolic syndrome.
Front Physiol. 2024 Feb 19;15:1365761. doi: 10.3389/fphys.2024.1365761. eCollection 2024.
6
Factors Affecting Dyslipidemia among Korean Adolescents: An Analysis Using the 8th Korea National Health and Nutrition Examination Survey (2021).
Children (Basel). 2023 Sep 28;10(10):1618. doi: 10.3390/children10101618.
7
Influence of 24-Week Yoga Intervention on Cardiovascular Risk Factors and Inflammatory Markers in Type 2 Diabetes.
Int J Yoga. 2023 Jan-Apr;16(1):27-33. doi: 10.4103/ijoy.ijoy_176_22. Epub 2023 Jul 10.
8
Fixed dose combination drugs for cardiovascular disease in a prolonged humanitarian crisis in Lebanon: an implementation study.
BMJ Open. 2023 Jan 25;13(1):e063668. doi: 10.1136/bmjopen-2022-063668.
9
Non-HDL-C and LDL-C/HDL-C are associated with self-reported cardiovascular disease in a rural West African population: Analysis of an array of lipid metrics in an AWI-Gen sub-study.
PLoS One. 2022 Dec 7;17(12):e0278375. doi: 10.1371/journal.pone.0278375. eCollection 2022.
10
COVID-19 and related social distancing measures induce significant metabolic complications without prominent weight gain in Korean adults.
Front Med (Lausanne). 2022 Sep 7;9:951793. doi: 10.3389/fmed.2022.951793. eCollection 2022.
本文引用的文献
1
Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines.
Am Heart J. 2011 Jun;161(6):1140-6. doi: 10.1016/j.ahj.2011.03.023. Epub 2011 May 11.
2
The importance of non-HDL cholesterol reporting in lipid management.
J Clin Lipidol. 2008 Aug;2(4):267-73. doi: 10.1016/j.jacl.2008.06.013. Epub 2008 Jun 28.
3
Major lipids, apolipoproteins, and risk of vascular disease.
JAMA. 2009 Nov 11;302(18):1993-2000. doi: 10.1001/jama.2009.1619.
4
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2.
5
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24. doi: 10.1016/j.jacc.2008.02.034.
6
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
Am J Cardiol. 2005 Aug 15;96(4):556-63. doi: 10.1016/j.amjcard.2005.04.019.
7
Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.
Circulation. 2004 Oct 26;110(17):2687-93. doi: 10.1161/01.CIR.0000145660.60487.94. Epub 2004 Oct 18.
8
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med. 2004 Apr 8;350(15):1495-504. doi: 10.1056/NEJMoa040583. Epub 2004 Mar 8.
9
Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.
Am J Cardiol. 2001 Aug 1;88(3):265-9. doi: 10.1016/s0002-9149(01)01638-1.
10
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
Zotero 插件